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Abstract
Purpose The therapeutic index (TI) is the range of doses at
which a medication is effective without unacceptable adverse
events. Drugs with a narrow TI (NTIDs) have a narrow win-
dow between their effective doses and those at which they
produce adverse toxic effects. Generic drugs may be substitut-
ed for brand-name drugs provided that they meet the recom-
mended bioequivalence (BE) limits. However, an appropriate
range of BE for NTIDs is essential to define due to the poten-
tial for ineffectiveness or adverse events. Flecainide is an an-
tiarrhythmic agent that has the potential to be considered an
NTID. This review aims to evaluate the literature surrounding
guidelines on generic substitution for NTIDs and to evaluate
the evidence for flecainide to be considered an NTID.
Methods A review of recommendations from various regula-
tory authorities regarding BE and NTIDs, and publications
regarding the NTID characteristics of flecainide, was carried
out.
Results Regulatory authorities generally recommend reduced
BE limits for NTIDs. Some, but not all, regulatory authorities
specify flecainide as an NTID. The literature review demon-
strated that flecainide displays NTID characteristics including
a steep drug dose–response relationship for safety and effica-
cy, a need for therapeutic drug monitoring of pharmacokinetic
(PK) or pharmacodynamics measures and intra-subject vari-
ability in its PK properties.
Conclusions There is much evidence for flecainide to be con-
sidered an NTID based on both preclinical and clinical data. A
clear understanding of the potential of proarrhythmic effects
or lack of efficacy, careful patient selection and regular mon-
itoring are essential for the safe and rational administration of
flecainide.
Keywords Antiarrhythmic drugs . Flecainide . Generic
drugs . Bioequivalence . Narrow therapeutic index . Safety
Introduction—general considerations on the therapeutic
index
The therapeutic index (TI; also known as therapeutic ratio) is a
ratio that compares the blood concentration at which a drug
causes a therapeutic effect to the amount that causes death (in
animal studies) or toxicity (in human studies) [1]. In animal
studies, the TI can be calculated as the lethal dose of a drug for
50 % of the population (LD50) divided by the minimum ef-
fective dose for 50 % of the population (ED50), i.e. TI=LD50/
ED50. This ‘academic’ definition of TI is easy to follow in
preclinical experiments but opens the door to variable inter-
pretations in clinical practice. In fact, the definition of a ther-
apeutic and/or toxic effect in both animals and humans is
highly dependent on the type of therapeutic or toxic effect
under consideration.
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In clinical practice, the TI is the range of doses at which a
medication appeared to be effective in clinical trials for a me-
dian of participants without unacceptable adverse effects. For
most drugs, this range is wide enough, and the maximum
plasma concentration of the drug (Cmax) and the area under
the plasma concentration–time curve (AUC) achieved when
the recommended doses of a drug are prescribed lie sufficient-
ly above the minimum therapeutic concentration and suffi-
ciently below the toxic concentration [2, 3]. Thus, it can be
expected that at the recommended prescribed doses, drugs
present clinical efficacy with an adequate safety margin.
The range between the ED50 and TD50 can be considerable,
depending on the medication. The larger the TI, the safer the
drug is. Conversely, a drug with a narrow TI has generally a
steep concentration–response relationship for efficacy, toxici-
ty or both so that there is a narrowly defined range between
risk and benefit. It is generally considered that a drug has a
good safety profile if its TI exceeds the value of 10. The
situation is quite different with the so-called narrow TI drugs
(NTIDs), where there is only a very small range of doses at
which the drug produces a beneficial effect without causing
severe and potentially fatal complications, i.e. small variations
in their plasma concentrations can result in an insufficient
therapeutic response or appearance of adverse toxic effects.
Sometimes, the term ‘critical dose drugs’ is used to refer to
drugs in which comparatively small differences in dose or
concentration may lead to serious therapeutic failures and/or
serious drug reactions [4]. Other terms also used include
‘drugs with a narrow therapeutic window’, ‘narrow therapeu-
tic range’, ‘critical dose drugs’ or ‘narrow therapeutic ratio’.
The US Food and Drug Administration (FDA) defines a
drug product as having an NTI when (a) there is less than a
twofold difference in median lethal dose (LD50) and median
effective dose values (ED50) or (b) there is less than a twofold
difference in the minimum toxic concentrations (MTC) and
minimum effective concentrations (MEC) in the blood and (c)
safe and effective use of the drug requires careful titration and
patient monitoring [4, 5]. A broader definition of an NTID has
also been proposed by the FDA in 2011 and is discussed in
BMedical considerations on the TI of flecainide^ and other
antiarrhythmic drugs (AADs).
Because of the small differences between their effective
and toxic doses, small changes in the dosage of NTIDs can
lead to significant changes in pharmacodynamic (PD) re-
sponse, and therefore their use should be individualised. This
may result in potentially subtherapeutic or toxic effects, par-
ticularly in patients with advanced age, with comorbidities or
receiving multiple medications.
The concept of an NTI is important for proper use of drugs
in medical practice. It is used by clinicians with the subjective
but useful notion that drug doses or plasma concentrations
associated with a desired therapeutic response are in close
proximity to those associated with adverse reactions. The
concept of NTI is also used by drug regulatory authorities in
the context of drug safety warnings in the summary of drug
characteristics of authorised drugs and in the context of guide-
lines and regulatory standards for bioequivalence (BE) studies
(see below).
This review examined the guidance provided from the var-
ious national regulatory authorities in relation to BE of NTIDs
with a focus on AADs and in particular on flecainide. Addi-
tionally, we analysed the possible concerns relating to the
substitution of generic drugs for brand name AADs or for
other generic medications.
Bioequivalence studies
In order to be considered a therapeutic equivalent to a brand
name drug, a generic drug product must meet pharmaceutical
equivalence and BE criteria. Drug products are pharmaceuti-
cal equivalents if they contain the same active ingredient(s),
have the same dosage form and route of administration and are
identical in strength and/or concentration. But generic prod-
ucts may contain different excipients such as colorants, pre-
servatives, lubricants and diluents that might lead to further
differences between the two products. It can be argued, how-
ever, that by definition excipients are inert substances with no
biological activity and generic excipients have to be previous-
ly used for approved drugs for which there is evidence that
they have not affected the safety or effectiveness [6].
According to the FDA, BE is defined as ‘the absence of a
significant difference in the rate and extent to which the active
ingredient or active moiety in pharmaceutical equivalents or
pharmaceutical alternatives becomes available at the site of
drug action (or bioavailability) when administered at the same
molar dose under similar conditions in an appropriately de-
signed study’ [7, 8]. In other words, if the innovator and ge-
neric drugs are bioequivalent, then they should exhibit equiv-
alent drug concentration–time profiles in the blood [9].
The BE can be established on the basis of theCmax, the time
taken for maximum plasma concentration to be reached
(Tmax), or the AUC, the area under the plasma concentration–
time curve from time 0 to the last sampling time [AUC(0→t)] and
AUC(0→∞) (the area under the plasma concentration–time curve
from time 0 to infinity for single doses or within a dosing interval
at steady state). The usually accepted criterion for concluding
that two products are bioequivalent is that the 90 % confidence
intervals (CIs) for the ratio between the test and the reference
geometric means for AUC and Cmax (determined using
log-transformed data) lie within the range of 80.00–125.00 %
in the fasting state [7, 9, 10].
The guideline on the investigation of BE of the European
Medicine Agency (EMA) indicated that in studies to deter-
mine BE after a single dose, the parameters to be analysed
areCmax and AUC0–t, or, when relevant, AUC0–72 h (in studies
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with a sampling period of 72 h) [11]. For these parameters, the
90 % CI for the ratio of the test and reference (T/R) products
should be contained within the acceptance interval of 80.00–
125.00 %. To be inside the acceptance interval, the lower
bound should be ≥80.00 % when rounded to two decimal
places, and the upper bound should be ≤125.00 % when
rounded to two decimal places.
Different opinions concerning the BE of NTID
Differences in drug response among patients are common
even after the plasma drug concentration has been adjusted
to a target value. Because of the very small margin between
a safe and lethal dose, NTIDs must be dosed carefully based
on plasma concentration, and patients should be monitored
closely for any signs of drug toxicity. Due to their potential
for ineffective and particularly adverse effects, NTIDs must be
kept within an extremely narrow range, which may not be
satisfied with current BE standards [12]. Within a population,
individual patients show quite substantial variability in re-
sponse to any one therapy (interindividual variability), and
even the same patient can present differences in drug response
from dose to dose during the course of drug therapy
(intraindividual/within-subject variability) [13–15]. Under
these circumstances, measures of population and individual
BE are proposed to bemore accurate thanmeasures of average
BE. Population BE takes into account interindividual varia-
tion and is the relevant criterion for a patient being started on a
new drug, while individual BE takes into account
intraindividual variation and is the relevant criterion for a pa-
tient being switched from one formulation to another [13].
Inter- and intraindividual variability are caused by a combina-
tion of demographic (gender, body weight or surface area, age
and race), gastrointestinal (first-pass metabolism, gastrointes-
tinal pH, motility, blood flow and bacterial flora), environ-
mental (smoking, diet, exposure to pollutants), genetic (asso-
ciated with variants in drug-metabolising enzymes and/or
drug receptors), therapeutic (drug interactions) and physio-
pathological factors (pregnancy, severity of the disease over
time, comorbidities, kidney or hepatic dysfunction) that affect
the pharmacokinetics (PK) and/or pharmacodynamics (PD) of
a given drug [16, 17]. Monitoring plasma drug concentrations
is useful for an NTID when much of the interindividual vari-
ability in response is accounted for variability in drug PK, but
it has little value when most of the variability is PD. An ex-
ample of inherited interindividual PK variability is the clear-
ance of flecainide related to CYP2D6 polymorphisms. Thus,
caution is warranted when considering generic substitution of
drugs that exhibit high interindividual variability or differing
PK properties in different patient populations because this
variability cannot be addressed by narrowing BE boundaries.
Finally, current studies to determine BE are performed in
young healthy volunteers who do not take any concurrent
medication, and it is assumed that BE in this homogeneous
population will equate to all patient populations. Patients with
tachyarrhythmias are generally older, present structural heart
diseases, are treated with several drugs and present rapid
changes in heart rate over time, leading to intraindividual var-
iability in drug PD/PK due to a decrease in cardiac output,
volume of distribution and organ perfusion. This population is
quite different from that in whom the average BE is
performed.
A summary of the BE criteria for general drugs versus
NTIDs, with a particular interest on flecainide, is presented
in Table 1. In 2010, the Committee for Medicinal Products for
Human Use of the EMA indicated that it is not possible to
define a set of criteria to categorise drugs as either NTIDs, and
cases must be considered individually based on clinical con-
siderations [11]. However, it is recognised that for specific
NTIDs, the acceptance interval for AUC should be tightened
from the conventional 80.00–125.00 % to 90.00–111.11 %
[11, 15, 18].Where Cmax is of particular importance for safety,
efficacy and drug level monitoring, the 90.00–111.11 % ac-
ceptance interval should also be applied [11]. Consequently,
the tightening acceptance limits for NTID apply both AUC
and Cmax. Furthermore, the EMA also states: ‘for the purpose
of BE requirements, NTIDs may be considered to be those for
which there is a risk of clinically relevant difference in effica-
cy or safety between two products even when the convention-
al criteria for BE (i.e. 90 % CI for T/R ratio for AUC and Cmax
within 80–125 %) are met’. However, the EMA did not men-
tion whether flecainide is an NTID.
The US FDA has not formally designated specific critical
dose/NTID or provided a comprehensive list of NTIDs, al-
though warfarin, levothyroxine, carbamazepine, lithium car-
bonate, digoxin, phenytoin, tacrolimus and theophylline are
categorised as NTIDs [19, 20]. The draft guidance on BE
studies for flecainide acetate did not mention this drug as an
NTID [21]. It should be emphasised that several drugs of the
above FDA list of NTIDs (e.g. carbamazepine, lithium) also
do not have a mention of their NTI nature in the draft or final
guidance document for their BE studies, whereas warfarin and
tacrolimus have this mention [22, 23]. However, Laurie Frueh,
medical officer from the FDA Office of Pharmaceutical Sci-
ences, in her presentation ‘Interchangeability of critical
critical-dose drugs: clinical perspectives’, included antiepilep-
tics, antiarrhythmics, inmmunosupressants and anticoagulants
as major drug classes included in this definition [4].
Because of the narrow margin between safe and lethal dos-
ages with NTIDs, some voices from healthcare providers, cli-
nicians, scientists, state regulators, pharmaceutical companies
and consumer advocates have expressed concern that bio-
equivalent generic and brand-name NTI/CD drugs may not
be equivalent in their effects on various clinical parameters
and proposed that generic substitution should not be
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applicable for NTID as they deserve special attention and
more rigorous BE standards.
The FDA presented the topic of BE for NTIDs in two
recent meetings of the Advisory Committee for Pharmaceuti-
cal Science and Clinical Pharmacology [4, 19, 24, 25]. In the
2010 meeting, the committee recommended that the agency
should develop a list of NTIDs with clear, specialised criteria
for including drugs on the list. The list should be made public
by the FDA and clearly define the mechanism for addition to
the list, the list should be dynamic and constantly monitored
and the list should focus on BE issues. Furthermore, the com-
mittee made a list of suggestions including ‘replication studies
are important’ and ‘the requirements for confidence intervals
should perhaps be narrower (90.00–111.11 %) and should
include 100 % (or 1.0)’ [19]. In the 2011 meeting, the FDA
recommended for NTIDs to conduct a four-way, two-se-
quence, fully replicated crossover design to assess the
within-subject variability of both the test and reference prod-
ucts and to use the reference-scaled average BE approach for
the statistical comparison of the relevant PK parameters [19,
26, 27]. The BE limits would change as a function of within-
subject variability of the reference product (reference-scaled
average BE). If reference variability is ≤10 %, then BE limits
are reference-scaled and narrower than 90.00–111.11 %. If
reference variability is >10 %, then BE limits are reference-
scaled and wider than 90.00–111.11 % but are capped at 80–
125 % limits. This proposal encourages development of low
within-subject variability formulations [19, 25, 26].
More recently, newly drafted FDA guidance reviews evi-
dence supporting the consideration of warfarin sodium [22]
and of tacrolimus [23] as NTIDs; both documents explained
the evidence on which the FDA considered warfarin and ta-
crolimus as NTIDs. The guidance onwarfarin recommended a
four-way, fully replicated crossover design in order to scale
BE limits to the variability of the reference product and com-
pare test and reference product within-subject variability [22].
Furthermore, the guidance described the method for statistical
analysis using the reference-scaled average BE approach for
NTIDs.
The Canadian Drug Regulatory Agency (Health Canada)
in its detailed 2012 Guideline on BE studies [28] did not make
a reference to NTI drugs, but they mentioned several excep-
tions that require modifications of the BE standards. This is
the case for the so-called critical dose drugs, defined as those
drugs where comparatively small differences in dose or con-
centration lead to dose- and concentration-dependent, serious
therapeutic failures and/or serious adverse drug reactions. For
these ‘critical dose drugs’, (a) the 90%CI of the relative mean
AUC of the test to reference formulation should be within
90.00–112.00 % and (b) the 90 % CI of the relative mean
Cmax of the test to reference formulation should be 80.00–
125.0 % inclusive. These requirements are to be met in both
the fasted and fed states. It is important to mention that
flecainide is listed in the non-limiting list of ‘critical dose’/
NTI drugs. Furthermore, the guideline mentions that due to
the nature of these drugs and possibility of serious adverse
Table 1 Different opinions on the BE of NTIDs with a particular interest in flecainide
Agency BE criteria for general drugs BE criteria for NTID Flecainide as an NTID
Foods and Drug Administration (FDA) 80.00–125.00 % 90.00–111.11 % No
European Medicines Agency (EMA) 80.00–125.00 % 90.00–111.11 % No
Danish Health and Medicines Authority 80.00–125.00 % 90.00–111.11 % The agency tightened the
BE limits for AADs
Federal Agency for Medicines and Health
Products (FAMHP) of Belgium
80.00–125.00 % 90.00–111.11 %
Health Protection and Food Branch (HPFB) of Canada 80.00–125.00 % 90.00–112.00 % Flecainide is considered a
critical dose drug
New Zealand Medicines and Medical Devices
Safety Authority (MEDSAFE)
80.00–125.00 % Yes
Japanese Institute of Health Sciences (NIHS) 80.00–125.00 % 90.00–111.11 % Digoxin, disopyramide and
quinidine, but not flecainide
Medicines Control Council (MCC) of South Africa 80.00–125.00 % Tighter limits are
considered for NTID
AADs are considered NTID
Therapeutic Goods Administration of Australia (TGA) 80.00–125.00 % 90.00–111.11 % No list of NTID
Agence Fédérale des Médicaments et des Produits
de Santé of Belgium
90.00–111.11 % Yes
French Agence Nationale de Sécurité des
Médicaments (ANSM)
Yes
Agencia Española de Medicamentos y
Productos Sanitarios (AEMPS)
80.00–125.00 % 90.00–111.11 % Yes
AADs antiarrhythmic drugs, BE bioequivalence, NTIDs narrow therapeutic index drugs
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effects, it may be necessary to conduct BE studies in patients
who are already receiving the drug as part of treatment rather
than in healthy volunteers, and it is highly recommended that
the study group be as homogeneous as possible with respect to
predictable sources of variation in drug disposition.
The New Zealand Medicines and Medical Devices Safety
Authority (MEDSAFE) considered that NTIDs, such as anti-
convulsants, antiarrhythmics, theophylline, warfarin, isotreti-
noin, cyclosporine and thyroxine, should not be considered
as interchangeable drugs [29, 30]. The regulatory guidelines
for medicines also stated that tighter limits for permissible dif-
ferences in bioavailability may be required for medicines that
have an NTI, serious dose-related toxicity, a steep dose/effect
curve or non-linear PKs within the therapeutic dosage range.
The Therapeutic Goods Administration of Australia (TGA)
employs a 90.00–111.11 % BE range instead of the 80–125 %
BE range for NTI drugs. This stricter criterion explains why
some drugs with an NTI (e.g. warfarin, phenytoin, lithium) do
not have generic brands, and switching is not an option in
Australia [31].
For the Japanese Institute of Health Sciences (NIHS), the
accepted BE acceptance criterion for NTIDs is 90.00–
111.11 %. They define NTIDs as those having less than a
twofold difference in the minimum toxic concentrations and
minimum effective concentrations in the blood and those for
which specific drug treatment control fees are approved as
remuneration for treatment [32]. The list of 26 NTIDs includes
several AADs, including digoxin, disopyramide and quini-
dine, but not procainamide or flecainide.
The Medicines Control Council (MCC) of South Africa
accepts the BE criteria (AUC and Cmax 90 % CI of T/R ratios
should fall within 80–125 %). However, the MCC presents a
list of ‘bioproblem’ drugs that includes NTIDs. Furthermore,
the substitution guidelines state that ‘unless adequate provi-
sion is made for monitoring the patient during the transition
period, substitution should not occur when prescribing and
dispensing generic medications having a narrow therapeutic
range’ [33].
Like the EMA, the Danish Health andMedicines Authority
requires tighter acceptance limits, i.e. 90.00–111.11 %, for
both AUC and Cmax for drugs with an NTI, including antiar-
rhythmic agents [34]. The Danish authorities accept that me-
dicinal products containing the NTIDs on their list are thera-
peutically equivalent because stricter BE criteria were applied,
and therefore generic substitution of NTIDs is authorised,
with some exceptions.
The Agence Fédérale des Médicaments et des Produits de
Santé of Belgium also considered that NTIDs, under certain
unspecified conditions, require a narrow (90.00–111.11 %)
BE range [35, 36]. They include a list of NTIDs where several
AADs, including amiodarone, digoxine, disopyramide,
flecainide, propafenone and sotalol (but not quinidine and
procainamide), were included. For the Agence, NTIDs are
considered to be ‘non-switchable’. The French ANSM
(Agence Nationale de Sécurité des Médicaments) has not
established an official list of NTIDs. However, flecainide is
mentioned as an NTID in the recommendations regarding
therapeutic interactions [37].
Finally, the Agencia Española de Medicamentos y
Productos Sanitarios of Spain (http://www.aemps.gob.es/)
has recently determined that flecainide should be considered
an NTID and as such cannot be substituted by pharmacists
[38].
Thus, BE guidelines from different representative countries
recognise the term NTI (or similar terms), and both the FDA
and EMA have discussed the possibility of narrowing the
limits of BE from 80.00–125.00 % to even 90.00–111.11 %.
As noted, antiarrhythmic agents appeared in the majority of
the lists of NTIDs.
Medical considerations on the TI of flecainide
In general, the concept of TI is not taken into consideration for
physicians in daily clinical practice, but the concept becomes
obvious to them when adverse reactions occur despite admin-
istration of a given drug at the recommended dosing ranges.
AADs are considered NTIDs from a clinical point of view for
both cardiologists and general practitioners, although the con-
cept of NTI is strongly influenced by the nature of the indica-
tion and the presence/absence of underlying heart disease.
It has been considered that NTIDs generally have the fol-
lowing characteristics [19, 20]:
& Steep drug dose–response relationship for both safety and
efficacy within the usual dosing range or narrow span
between effective drug concentrations and concentrations
associated with serious adverse drug reactions. Serious
adverse reactions are defined as those which may be per-
sistent, irreversible, slowly reversible, or life-threatening,
which could result in in-patient hospitalisation or prolon-
gation of existing hospitalisation, persistent or significant
disability or incapacity, or death.
& They are subject to therapeutic drug monitoring based on
PK or PD measures to ensure safe and effective use of the
drug.
& Small within-subject variability. Otherwise, patients will
routinely experience toxicity and lack of efficacy.
Flecainide as an antiarrhythmic drug
Flecainide is a class IC AAD. In the European Society of
Cardiology (ESC) and ACCF/AHA 2012 guidelines for the
treatment of atrial fibrillation (AF), flecainide is recommended
Eur J Clin Pharmacol (2015) 71:549–567 553
in the management of patients without structural heart dis-
ease (1) for the pharmacological cardioversion of recent-
onset AF (recommendation class I, level A), (2) to enhance
success of direct current cardioversion and prevent recurrent
AF (recommendation class IIa, level B) and (3) for long-
term rhythm control (recommendation class I, level A)
[39–41] (see Supplementary Table 1 for more details on
the clinical indications and contraindications of flecainide
as AAD).
Evidence that flecainide is an NTID
When treating cardiac arrhythmias, where a recurrence might
have significant or serious consequences or where the AAD
can produce a potentially life-threatening proarrhythmic
event, the clinical challenge is to ensure that drug availability
at its cardiac receptor site remains constantly within the ther-
apeutic range. Thus, antiarrhythmic therapy represents a chal-
lenge for clinicians because potential inefficacy or serious
proarrhythmia becomes the issue in a particular patient even
though clinical therapeutic BE may hold true for most
patients.
The ACCF/AHA (American College of Cardiology
Foundation/American Heart Association) 2011 Health Policy
Statement on Therapeutic Interchange and Substitution in-
cludes a table with examples of NTIDs [42]. The first group
of NTIDs was the AADs, and flecainide was included as a
representative agent together with digoxin, quinidine, procain-
amide and disopyramide. Furthermore, as already mentioned,
from a regulatory point of view, Health Canada and Spain
specifically mention flecainide as an NTID, and other coun-
tries, such as Denmark, New Zealand and Belgium, state that
AADs have an NTI without specifically mentioning
flecainide; Belgium lists flecainide as an NTID in a document
referring to prescriptions under non-trade names. Finally, in
the treatment of ventricular arrhythmias, flecainide has also
been explicitly described as an NTID [3, 43, 44], and two
recent comprehensive reviews on the safety profile of
flecainide, although they did not mention the term NTI, de-
scribe the drug as having such a profile [45, 46].
As already mentioned, flecainide presents the characteris-
tics of an NTID (see Table 2).
A steep drug dose–response relationship for both safety
and efficacy
Therapeutic trough plasma levels of flecainide associated with
greater than 90 % suppression of PVBs range between 200
and 1000 ng/mL [45, 47–51], although cardiac (i.e. conduc-
tion defects or bradycardia and ventricular proarrhythmia) or
non-cardiovascular adverse reactions may occur in some pa-
tients when plasma flecainide levels are ≥700–1000 ng/mL
[47, 52–55]. While severe adverse events have been associat-
ed at doses twice above the upper limit [56], they may also
occur within the therapeutic plasma levels in some patients
with cardiovascular diseases [47, 57].
To study the relationship between plasma levels of
flecainide and the suppression of ventricular arrhythmias, a
decreasing multiple oral dosage regimen (200–50 mg BID)
was administered over 12 days in patients with chronic VPBs
[47–51]. Maximum plasma levels (413–789 ng/mL) were as-
sociated with almost complete (>95 %) suppression of ar-
rhythmias [47–51]. As dose decreased, plasma levels declined
to levels below about 230 ng/mL that were associated with a
reappearance (<70 % suppression) of arrhythmias. These re-
sults suggest that the minimum range of therapeutic plasma
levels of flecainide for VPBs is approximately 200–400 ng/
mL and that 95 % suppression of VPBs occurs at concentra-
tions up to 800 ng/mL.
In patients with supraventricular tachyarrhythmias treated
with oral flecainide (150–300 mg daily), the trough plasma
levels vs effect relationship was described as steep [58]. The
mean serum flecainide trough concentrations differed signifi-
cantly between patients with and without palpitations, but the
incidence of palpitations was 65 % at serum flecainide con-
centrations <300 ng/mL and 11 % at ≥300 ng/mL, which
indicates that the effective drug plasma concentrations should
be maintained at ≥300 ng/mL.
Salerno et al. compared the side effects with flecainide
trough levels and ECG intervals in patients with ventricular
arrhythmias treated with 100–200mgBID for 34months [57].
The incidence of adverse cardiovascular effects rose steadily
with increasing flecainide plasma levels, but the maximum
suppression of VPBs was achieved at flecainide plasma levels
of 250–500 ng/mL (Fig. 1). Interestingly, cardiovascular ad-
verse effects related to drug plasma levels but not to the dose
of flecainide, so to predict the occurrence of adverse effects,
one must monitor some index of the concentration of the drug
in plasma. As observed in Fig. 1, the probability of
Table 2 Flecainide presents the pharmacological profile of an NTID
NTI characteristics of flecainide
Steep concentration–response relationships for efficacy,
toxicity or both in the usual dosing interval [46, 49, 53, 54, 59, 96]
Dosing generally needs to be titrated according to clinical
response [43, 44, 47]
Small differences in dose or blood concentration may lead to serious
therapeutic failures and/or adverse drug reactions [43, 49, 54]
There may be a potential for serious clinical consequences in the event of
too low or high concentrations [43, 45, 47, 53, 59]
Periodic monitoring of plasma levels is required in patients with severe
renal failure or severe hepatic disease [52]
Drug overdose with flecainide is frequently fatal [43, 47, 52, 137]
NTID narrow therapeutic index drug
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Fig. 1 Plasma levels and side effects of flecainide acetate. a Flecainide
plasma levels, per cent suppression of VPCs from pretreatment and per
cent of plasma levels associated with cardiovascular side effects for
flecainide plasma levels grouped in 250-ng/mL increments. b The
probability of cardiovascular side effects compared with the change in
ECG intervals from baseline (n=40 for PR and n=36 for QRS interval).
Bundle branch block was excluded from analysis for comparison of
change in QRS interval with cardiovascular side effects. c The
probability of cardiovascular side effects occurring is compared with
trough plasma flecainide levels by use of the Kaplan–Meier product
limit estimator for all 43 patients (open circles). The efficacy/plasma
concentration curve for 90 % suppression of VEDs is also shown for
those 33 patients with available data for both efficacy and flecainide
levels (closed symbols). Twenty-eight of the 33 patients achieved at
least 90 % suppression of VEDs. RBBB right bundle branch block,
CHF congestive heart failure, LBBB left bundle branch block, VPBs
premature ventricular beats, VT ventricular trachycardia (taken from
Salerno et al.) [57]
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cardiovascular adverse effects begins to rise at a plasma level
of approximately 750 ng/mL and reaches 50 % at 1500 ng/
mL. The figure also shows the percentage of patients achiev-
ing 90% suppression of VPBs at different drug plasma levels.
The correlation between both curves described the therapeu-
tic–toxic window, which is in the range of flecainide plasma
levels between 381 ng/mL (at least 50 % probability of effi-
cacy) and 710 ng/mL (less than 10 % probability of cardio-
vascular side effects). The risk of cardiovascular side effects
increases at higher drug plasma levels, and the probability of a
cardiovascular event begins to rise sharply at increases of
approximately 40 ms in both PR and QRS intervals from
baseline. These results confirmed that flecainide dosing is
complicated by the steepness of the dose–response for both
safety and efficacy.
The steepness of the dose–response relationship and the risk
of proarrhythmia increases in the presence of structural heart
disease
The presence of structural heart disease increases the risk of
flecainide-induced proarrhythmia. The steepness of the dose–
response relationship for drug safety was compared in dogs
with 72-h-old healed myocardial ischaemia (MI) and in dogs
exposed to acute myocardial ischaemia induced by 10-min
coronary occlusions and separated by 30 min of reperfusion
[59, 60]. Flecainide-induced proarrhythmia in dogs with
healed MI was reported at flecainide plasma concentrations
of 0.8–5.6 mg/kg (2–14 μmol/L) [59, 61, 62], which are gen-
erally higher than the accepted therapeutic range of 200–
700 ng/mL (0.5–1.7 μmol/L). Ventricular proarrhythmia oc-
curred in 31 % of healthy dogs, in 79 % of MI dogs and 55 %
of dogs with acute ischaemia. As shown in Fig. 2, flecainide-
induced proarrhythmia occurred at therapeutic concentrations
in dogs with acuteMI (EC50 0.75μmol/L), concentrations that
were 20-fold lower than those producing proarrhythmia in
dogs with healed MI (EC50 17 μmol/L) [60]. Furthermore,
flecainide-induced proarrhythmia in acute MI generally was
ventricular fibrillation (VF), whereas with healed MI
proarrhythmia was an inducible sustained VT. These findings
strongly suggest an interaction between flecainide and acute
myocardial ischaemia, which could explain the excess of
deaths in the CAST (Cardiac Arrhythmia Suppression Trial)
[63].
In the CAST, the rate of death and non-fatal cardiac arrest
increased by 2.3-fold after 10 months of treatment with
flecainide in a population with structural heart disease [63].
Interestingly, the excess mortality occurred at non-toxic
flecainide doses and was due to sudden cardiac death (SCD)
rather than sustained VT. The incidence of SCD was lower
when treated with flecainide in combination with a β-blocker
than with flecainide alone [64].
As suggested by the authors, acute myocardial ischae-
mia might facilitate the occurrence of fatal arrhythmias, or
the negative inotropic effects of flecainide may have re-
sulted in severe hypoperfusion or increased myocardial
oxygen demands during acute ischaemia. Thus, it seems
that excess of deaths, myocardial ischaemia and
proarrhythmia are interrelated both in experimental models
and in post-MI patients. Additionally, the CAST showed
that the use of flecainide is not recommended to treat
asymptomatic or mildly symptomatic ventricular arrhyth-
mias in patients with LV dysfunction after MI as it in-
creases the mortality risk.
Several studies have demonstrated that flecainide markedly
increases the episodes of sustained VT in patients with a his-
tory of sustained VT and impaired LV function by almost
20 %, while in patients with stable nonsustained ventricular
arrhythmias and preserved LV function, the risk of
proarrhythmia appears to be very small [54, 65].
In patients with sustained VT treated with flecainide, 80 %
of proarrhythmic events were new or worsened ventricular
tachyarrhythmias that occurred within 14 days of the onset
of therapy; the remainder was increased frequency of PVCs
or new supraventricular arrhythmias. In patients with a history
of MI, LV dysfunction and/or an episode of cardiac arrest, the
incidence of new or exacerbated ventricular arrhythmias was
13 %, and the incidence of fatal proarrhythmic events was
0.5 % when the dosage was initiated at 200 mg/day and did
not exceed 300 mg/day. Using a higher initial dose (400 mg/
day), the incidence of proarrhythmic events was 26%, and the
incidence of fatal proarrhythmic events was about 10 %.
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Fig. 2 Concentration–response curves for flecainide proarrhythmia in
dogs with acute myocardial ischaemia (AMI) or chronic myocardial
infarction (CMI) 72 h after coronary artery ligation (taken from Nattel)
[60]
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Patients with sustained VT experienced more frequently new
or worsened heart failure (HF) compared with those with sup-
raventricular arrhythmias. Interestingly, the elimination half-
life was longer, and plasma clearance was slower in patients
with HF [47] as well as in patients with ventricular arrhyth-
mias, even in the absence of HF [43]. Of note is that the co-
administration of flecainide with other AADs increased the
risk of proarrhythmias, and thus it should be avoided [54, 66].
All of these experimental and clinical studies indicated that
the steepness of the dose–response to flecainide as well as the
risk of proarrhythmia increases in the presence of structural
heart disease, so small changes in drug plasma concentrations
can lead to severe proarrhythmia. This explains why
flecainide use is contraindicated in patients with AF and a
history of structural heart disease involving myocardial is-
chaemia, hypertrophy and abnormal LV function or conges-
tive HF [39, 40, 67, 68].
Conduction abnormalities
At therapeutic concentrations, flecainide dose-dependently
decreases intracardiac conduction and prolongs the PR, QRS
and QT intervals, the effect of the drug being more marked on
the His-Purkinje system [45, 46, 51, 55, 69, 70]. The QT
prolongation is due to a widening of the QRS complex, while
the JT interval and the rate-correctedQT interval (QTc) remain
almost unchanged. This explains the rare cases of torsade de
pointes caused by flecainide. Flecainide also prolongs atrial,
AV nodal and ventricular refractoriness, although the effects
on refractoriness are less pronounced than its effects on intra-
cardiac conduction [43–46, 55, 61–63, 69, 71]. Approximate-
ly one third of patients may develop new first-degree AV heart
block (PR interval ≥0.20 s). Therefore, it is recommended to
avoid the combination of flecainide with other AADs as the
combination increases the depression of intracardiac conduc-
tion and contractility and increases the risk of proarrhythmia.
The combination of AADs of different classes implies strict
surveillance and control by repeated ECCs, and the combina-
tion of AADs of the same class must be avoided.
Even at therapeutic concentrations, flecainide may cause
the conversion of AF to a slow atrial flutter at a rate of
200 bpm (1C flutter), and because flecainide does not slow
down AV conduction, it may result in a 1:1 AV conduction
with a rapid ventricular response [71–73]. Thus, when
flecainide is given for prophylaxis against recurrent paroxys-
mal AF or atrial flutter, AV nodal blocking drugs should be
routinely co-administered [40]. Additionally, in some patients,
a long asystolic pausemay also occur at the time of conversion
of AF to sinus rhythm [45, 46, 74]. These adverse effects
explain why it is recommended that in patients with AF the
first loading oral dose of flecainide should be administered
under strict ECG and clinical control in a hospital setting.
Haemodynamic effects
Both bradycardia and tachycardia have been reported follow-
ing flecainide administration [43, 54, 55], and an increase in
the corrected sinus node recovery time has been described in
patients with sinus node dysfunction [53, 55, 56, 66–68].
Multiple doses of oral flecainide had minimal effects on LV
ejection fraction in patients with nearly normal ventricular
function [43], but flecainide exerts a negative inotropic effect,
particularly when given intravenously, and may cause or
worsen heart failure in patients with coronary heart disease
(CAD), pre-existing HF (New York Heart Association func-
tional class III or IV) or LV dysfunction (LVejection fraction
<30 %) [55, 65, 75–79]. New or worsened HF has been found
in 0.4 % of patients (1/22 %) with supraventricular arrhyth-
mias [77] and in 6.3 % of patients (20/317) with PVCs, non-
sustained or sustained VT after a mean of 7.9 months of
flecainide therapy [67, 68]. However, 25.7 % of patients (78/
304) with a history of HF developed worsened HF during a
mean duration of 5.4 months of flecainide therapy. This ex-
plains why flecainide is contraindicated in patients with con-
gestive HF or LV dysfunction.
Therapeutic drug monitoring based on PK or PD measures is
needed to ensure safe and effective use of the drug
As small changes in flecainide plasma concentrations can lead
to severe proarrhythmia, the treatment should start at low dos-
ages that should be increased gradually while monitoring the
ECG and/or drug plasma levels to avoid toxic levels (>700–
1000 ng/mL) [51, 54, 63]. Nevertheless, the close relationship
of drug efficacy and cardiovascular effects with flecainide
plasma levels and ECG intervals allows the administration
of flecainide at an acceptable safety level [57]. The blockade
of cardiac Na+ channels slows down intracardiac conduction
and prolongs the duration of the QRS complex of the ECG.
The QRS widening has been shown to be a surrogate marker
for the electrophysiological and therapeutic effect and allows
monitoring of cardiac conduction safety [80]. Widening of
QRS complex higher than 25 % of the baseline values implies
that the dosage must be reduced due to its narrow TI [46]. In
case there is a change in the dosage of flecainide or in case the
co-prescription of drugs is able to modify cardiac conduction,
the patients, mainly those with intracardiac conduction abnor-
malities, will be carefully monitored by repeated ECGs. In the
same way, it is necessary to control the ECG in case of change
in the formulation or the presentation of flecainide due to its
narrow TI [46].
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Flecainide is predominantly excreted in the urine and ac-
cumulates in patients with renal failure [81]. Periodic moni-
toring of plasma levels and ECG is required in patients with
severe renal failure or severe hepatic disease. Although the
absorption and volume of distribution of flecainide are unaf-
fected in patents with renal impairment, the plasma elimina-
tion half-life is significantly prolonged in patients with mild to
moderate renal impairment (10–30 h; mean creatinine clear-
ance 37.8mL/min/1.72m2) and in patients with stage 5 chron-
ic kidney disease (up to 58 h) compared with patients with
normal renal function (6–15 h; mean creatinine clearance
106.5 mL/min/1.72 m2) [43, 44, 81–83]. Multiple dosing of
100 mg BID in patients with impaired renal function can also
result in a longer elimination half-life (45–190 h) and a higher
plasma flecainide concentration than single daily dosing [83,
84]. Thus, lower starting and maintenance doses and frequent
monitoring of plasma levels and ECG parameters are recom-
mended in patients with moderate to severe renal dysfunction
[85]. Monitoring is particularly relevant in patients undergo-
ing dialysis because flecainide is poorly dialysed. Flecainide
drug monitoring (plasma levels and ECG changes) are indi-
cated in older patients who present an age-dependent decrease
in renal function and multiple comorbidities frequently asso-
ciated with structural heart diseases (CAD, hypertension, HF,
chronic kidney diseases) which result in polypharmacy and
increased risk of drug–drug interactions and proarrhythmic
effects. Flecainide plasma half-life also increases (19 h) in
patients with chronic heart failure as compared with normal
subjects [47].
One study evaluated how and to what extent NTIDs (in-
cluding flecainide), compared with other drugs, were associ-
ated with drug-related problems (DRPs) in 827 patients from
internal medicine and rheumatology departments from five
Norwegian hospitals. The study found that NTIDs were sig-
nificantly more often associated with DRPs than the non-
NTIDs 40 versus 19% of the times they were used [86]. Three
categories of DRPs were significantly more frequently found
for NTIDs: non-optimal dose, drug interactions and need for
monitoring. These findings demonstrate a particular need for
drug surveillance in hospitals to avoid serious consequences
of DRP.
Variability in the PK properties of flecainide
Oral flecainide is rapidly and nearly completely absorbed
(bioavailability 90–95 %), reaching Cmax values within 2–
3 h and steady state levels within 3–5 days, and it is not altered
if it is taken with food. Flecainide is a substrate and an inhib-
itor of the cytochrome P450 CYP2D6 and presents an appar-
ent plasma half-life that averages approximately 20 h but is
quite variable (range 7–30 h) after multiple oral doses in pa-
tients with PVBs [45–47]. Flecainide’s disposition kinetics are
partly dependent on the CYP2D6 genetic polymorphism
[87–92]. Approximately 7–10 % of Caucasians and 1–3 %
of Asians are poor metabolisers of drugs metabolised by
CYP2D6 [93, 94]. Approximately 30 % (range 10–50 %) of
the dose of flecainide is excreted unchanged in urine, mainly
by glomerular filtration, but some active tubular secretion may
also occur; its metabolites are excreted in urine principally as
conjugates [45, 46].
The mean elimination half-life of oral flecainide was found
to be 12 h (SD 2.8) and the metabolic clearance 292 (64) mL/
min in poor metabolisers compared with 6.9 h (0.9) and 726
(112) mL/min (both P<001), respectively, in rapid
metabolisers, while renal clearance did not differ between
the groups [92]. However, since the primary route of elimina-
tion for flecainide is renal and the proportion of a dose that
undergoes hepatic metabolism is small, the role of inter-
individual variations in CYP2D6 activity is unlikely to be
clinically significant. Even so, a CYP2D6 interaction could
become clinically relevant in patients with renal dysfunction.
Recently, it has been demonstrated that the CYP2D6 genotype
is a determinant factor of age-related decline in flecainide
clearance [88]. The metabolic clearance was decreased age-
dependently in a curvilinear fashion greater than 60 years for
heterozygous extensive metabolisers (het-EMs) and greater
than 55 years for intermediate metabolisers (IMs) and poor
metabolisers (PMs). The reduction in metabolic clearance in
elderly (70 years) patients compared with middle-aged
(52 years) patients was different among the CYP2D6 geno-
type groups: 22.1 and 49.5 % in CYP2D6 IMs and PMs,
respectively, with no change in homozygous extensive
metabolisers (hom-EMs). Because an 11.4 % reduction in
estimated glomerular filtration rate in elderly patients com-
pared with middle-aged patients corresponded to a 6.1 % de-
cline in flecainide clearance, the age-related decline in
flecainide clearance was 6.1 % in hom-EMs, 16.3 % in het-
EMs and 28.9 % in IMs/PMs groups.
Although these differences will not usually be of clinical
importance, they may have a significant impact in patients
with chronic kidney disease and/or treated with other drugs
that could affect the hepatic metabolism of flecainide. In fact,
in patients with PM/PM CYP2D6 genotype and renal insuffi-
ciency, flecainide has been associated with death [95]. Fur-
thermore, the PK of flecainide differs between subjects with
the CYP2D6 wild-type (*1 or *2) allele and the *10 allele in
Japanese patients with supraventricular tachyarrhythmia using
routine therapeutic drug monitoring data, which confirms that
these differences may be clinically relevant in the East Asian
population [90]. PK interaction with paroxetine, a potent in-
hibitor of CYP2D6, has been reported in healthy volunteers
who had the CYP2D6*10 allele, which is frequent in Asians
with clinical consequences (flecainide-induced delirium) [93,
96].
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The flecainide elimination rate from plasma can be mark-
edly slower in patients with significant hepatic impairment. In
these patients, flecainide should be used only when the poten-
tial benefits clearly outweigh the risks, and if used, close mon-
itoring (ECG and drug plasma levels) is required. Patients
with HF had slightly longer half-lives (19 vs 14 h in healthy
subjects) and lower mean plasma clearance (8.1 vs 10.2 mL/
min/kg) [55].
Safety profile of flecainide
Despite all of these conditions, when used in appropriately
selected patients, flecainide presents a good safety profile as
demonstrated by more than 25 years’ of cumulative experi-
ence in Europe and the USA [45, 46, 55].
Because of the concern about the safety of flecainide fol-
lowing the publication of the CAST trial, the database of 236
patients with supraventricular arrhythmias treated in the USA
with flecainide was obtained from 3M Pharmaceuticals and
compared with that in a research arrhythmic clinic, the Duke
population (154 patients) [97]. The 6-year survival functions
of these two populations, estimated by Kaplan–Meier tech-
nique, did not differ significantly. This finding demonstrated
that the increase in mortality found in patients with ventricular
arrhythmias in the CAST trial cannot be extrapolated to pa-
tients with supraventricular arrhythmias.
Recent clinical trials have reported a good tolerability pro-
file for flecainide in groups of appropriately selected patients,
i.e. when patients with HF, LV dysfunction, cardiac hypertro-
phy and/or CAD were excluded in line with current treatment
guidelines [39–41, 98].
When used in patients with supraventricular arrhythmias
without detectable structural heart disease and when drug
plasma levels are maintained within the therapeutic range
(0.2–1 μg/mL), flecainide has been shown to have a good
safety profile, and it may contribute to suppression of AF- or
SVT-related symptoms. In a meta-analysis of 122 prospective
studies conducted in 4811 patients (mean age 55±13 years,
60 % male) with supraventricular arrhythmias and no signif-
icant signs of LV damage, with a mean exposure time of 241±
224 days, the rate of proarrhythmic events was significantly
lower in flecainide (mean dose 216±65 mg/day) compared
with placebo recipients (2.7 vs 4.8 %, P<0.001) [99]. In this
analysis, there was no significant difference between the
flecainide and control groups in the rate of SCD or total mor-
tality, although there were 120 proarrhythmic episodes ob-
served in 120 flecainide-treated patients and 88 in control
patients (P<0.001). The yearly all-cause mortality rate was
estimated to be 0.397 per 100 person-years. Of the cardiac
deaths, all but two occurred in patients with CAD. Compared
with controls, flecainide was associated with a lower
incidence of proarrhythmic episodes (2.7 vs 4.8 %), angina
symptoms (1 vs 1.3 %), hypotension (0.8 vs 1.3 %), diarrhoea
(0.7 vs 2.8 %), headache (2.0 vs 2.9 %) and nausea (1.6 vs
1.8 %), and less than 5 % of patients receiving flecainide
discontinued treatment due to adverse effects [99]. These re-
sults confirmed the importance of selecting patients without
structural heart disease before initiating the treatment with
flecainide.
In a study evaluating the cardiac safety of the 200-mg con-
trolled-release formulation of flecainide in the prevention of
paroxysmal AF, the mean maximumQRS increase from base-
line was 11.4 %, and only four patients had a maximum QRS
value >100ms under treatment [100]. Themost frequent drug-
related proarrhythmic effects were bradycardia (13.2 %), ven-
tricular extrasystoles (10.6 %), AV block (4.0 %), supra-
ventricular tachycardia (2.2 %), bundle branch block (1.8 %)
and AF (1.3 %). New or worsened arrhythmias occurred in
1 % of patients with PSVT and in 0.4 % of patients with
paroxysmal AF/flutter treated with oral flecainide, while
10.5 % of patients with chronic AF developed ventricular
tachyarrhythmias; therefore, flecainide is not recommended
in these patients.
A nationwide study enrolled 141,500 patients admitted
with AF in Denmark from 1995 to 2004 [101]. In this unse-
lected population, the use of AADs, including flecainide, was
not associated with an increased risk of death. The annualised
mortality rate in the flecainide cohort (n=3356; mean dosage
of 205.6 mg) was 2.54 per year per 100 person-years, which
compares favourably with the corresponding rates for patients
treated with propafenone (4.25), sotalol (5.29) and amioda-
rone (7.42). This study confirmed that in selected patients with
AF, treatment with flecainide was not associated with in-
creased risk of death. Despite the promising results, this study
was limited by its retrospective non-randomised nature.
However, other studies have demonstrated that flecainide is
effective in preventing AF recurrences, but even in this popu-
lation flecainide still carries a clinically significant risk of
potentially severe adverse events at therapeutic doses [52,
102–105]. Flecainide-induced ventricular proarrhythmia man-
ifests as monomorphic wide QRS tachycardia or as polymor-
phic VT or VF. Factors associated with ventricular
proarrhythmia risk include decreased LV function, ventricular
scar tissue, too high a dose and/or rapid dose increases. Pre-
monitory signs on the surface ECG include excessive in-
creases in QRS duration [73, 106, 107].
One study evaluated the cardiac safety of 200-mg con-
trolled-release formulation of flecainide in the prevention of
paroxysmal AF in 227 patients. After 24 weeks of treatment,
the incidence of paroxysmal AF decreased from 28.6 to 11 %,
131 patients (71.8 %) had a QRS duration increase of <15 %
of the patients and 34 patients (18.8 %) had a QRS increase
≥25 % [100]. Bradycardia (13.2 %) and ventricular
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extrasystoles (10.6 %) were the most frequently identified
proarrhythmic effects, while atrio-ventricular block (4.0 %),
supraventricular tachycardia (2.2 %), bundle branch block
(1.8 %) and AF (1.3 %) were the most frequent drug-related
cardiac adverse events. Almost 7 % of patients discontinued
therapy due to cardiac adverse events.
In another study, 112 patients with paroxysmal (51 %) or
persistent (49 %) AF (mean age 60±11 years) were treated
with flecainide (mean dose 203±43 mg/day) [108]. Eight
deaths were reported during a mean follow-up of 3.4 years.
Three deaths were classified as SCD and occurred at 9 days,
20 and 63 months after the start of treatment. Six patients
discontinued the treatment due to proarrhythmia. Thus, the
incidence of SCD or proarrhythmia was 8 %, resulting in an
annual incidence of almost 2.5 %. Compared to the general
population, the standardised mortality ratios were 1.6 (95 %
CI 0.68–3.09) for all-cause mortality and 4.2 (95 % CI 1.53–
9.06) for death from cardiovascular disease during flecainide
exposure. These harmful effects were not prevented by careful
evaluation during drug initiation and follow-up or by treat-
ment with AV-blocking agents, which confirm the
proarrhythmic risk of flecainide.
In previous studies, one randomised controlled trial that
compared flecainide with placebo [109] and five that com-
pared flecainide with an alternative anti-arrhythmic treatment
in AF populations [110–114] describe eight deaths in the AF
population receiving flecainide (three because of non-cardiac
causes, four because of structural heart disease; no informa-
tion available in the remaining case). Death occurred between
1 day and 2 months after flecainide treatment initiation. No
deaths were reported in the 313 patients in another six studies
with a median flecainide exposure time of 12 months
[115–120]. In 568 patients with paroxysmal atrial flutter/AF
treated with oral flecainide, VT appeared in 0.4 % (2/568) of
these patients. Conversely, in 19 patients in the literature with
chronic AF, two (10.5 %) experienced VT or VF. Therefore,
flecainide is not recommended in this population [67, 68]. In
225 patients with supraventricular arrhythmia (108 with par-
oxysmal supraventricular tachycardia and 117 with paroxys-
mal AF), there were nine (4 %) proarrhythmic events; seven
episodes were exacerbations of supraventricular arrhythmias
and two were ventricular arrhythmias, including one fatal case
of VT/VF and one wide complex VT, both in patients with
paroxysmal AF and known CAD [67, 68].
A recent analysis of 56 studies comprising 20,771 patients
who recovered sinus rhythm after AF assessed the effect of
long-term treatment with AADs on death, stroke and embo-
lism, adverse effects, pro-arrhythmia and recurrence of AF.
Several class IA (disopyramide, quinidine), IC (flecainide,
propafenone) and III (amiodarone, dofetilide, dronedarone,
sotalol) AADs significantly reduced the recurrence of AF
(OR 0.19 to 0.70, number needed to treat 3 to 16). However,
all of these AADs increased withdrawals due to adverse
effects, and all but amiodarone, dronedarone and propafenone
increased pro-arrhythmia, and some of them (disopyramide,
quinidine and sotalol) may increase mortality [121].
In another direct meta-analysis, all of these AADs were
shown to be efficacious at reducing AF recurrence. Treat-
ment withdrawals specifically due to adverse effects were
significantly increased for all AADs, and all drugs were
associated with an increased risk of proarrhythmia com-
pared with placebo. Based on a limited number of patients,
flecainide showed an increase in the risk of serious adverse
events compared with placebo (OR 10.36, 95 % CI 1.26–
58.24) [102, 122].
Flecainide can organise and slow down the rate of AF,
converting it to atrial flutter, which in some patients (3.5–
5 %) with a particularly slow atrial rate may result in 1:1 AV
conduction with a rapid ventricular response [72, 73]. This
complication is a risk that has limited the prescription of
flecainide in patients with supraventricular arrhythmias and
is more likely to occur in the presence of adrenergic stimula-
tion. Drugs inducing the prolongation of AV conduction time
nodes, β-blockers, calcium antagonists and possibly digoxin,
have been proposed as useful concomitant medication during
treatment with class IC antiarrhythmics.
Risk of ventricular proarrhythmia
The major concern with starting antiarrhythmic therapy for
AF is the potential to induce ventricular proarrhythmia. Esti-
mating the risk for ventricular arrhythmia is particularly im-
portant in deciding whether to initiate AAD therapy under
close in-patient monitoring or on an outpatient basis.
Flecainide, like other AADs, can induce the occurrence of a
more severe arrhythmia than the arrhythmia for which it has
been prescribed. It can also increase the heart rate of a previ-
ously diagnosed arrhythmia or worsen the severity of symp-
toms. A spontaneous variation of the arrhythmia due to the
patient’s condition may be difficult to distinguish from a wors-
ening due to the drug itself. The occurrence of more frequent
or polymorphic premature ventricular complexes implies that
the treatment must be stopped. In case of heart failure history,
due to the negative inotropic effect of the drug, flecainide will
be prescribed under a strict surveillance of cardiac function in
patients with a history of symptoms suggestive of heart failure
[39, 40, 45, 46, 55].
In one study, flecainide was administered to 152 patients
(100–400 mg orally to 46; 2 mg/kg intravenously to 106) over
a period of 22 months [66]. Fourteen patients (8.1 %) devel-
oped proarrhythmic effects. Five patients developed new ven-
tricular tachyarrhythmias— three VF and two VT (three of
these patients had pre-existing ventricular arrhythmias); two
of these patients were taking other AADs, and proarrhythmic
effects occurred with both normal and high flecainide concen-
trations. Two patients developed supraventricular
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tachyarrhythmias, and seven experienced bradyarrhythmias.
In one patient, flecainide resulted in an increase of atrial flutter
cycle length, which resulted in the development of 1:1 atrio-
ventricular conduction rate and, overall, a faster ventricular
rate.
An initial survey performed in 544 patients with ventricular
arrhythmias by the manufacturer following the distribution of
an Adverse Effects Questionnaire found a proarrhythmic re-
sponse in 44 (8 %); 33 of these patients developed new or
worsened ventricular tachyarrhythmias. Of the 44 patients
who had a proarrhythmic response, 30 (11.8 %) were among
the 254 patients with haemodynamically significant VTor VF
and advanced structural heart diseases, whereas the incidence
of ventricular proarrhythmia decreased to 4.2 % in patients
with chronic non-sustained ventricular arrhythmias [54].
However, the population enrolled in this survey included pa-
tients with decreased LV function, previous MI, history of
sustained VT or concomitant treatment with other class I
AADs, i.e. patients in whom the administration of flecainide
is presently contraindicated. Indeed ventricular proarrhythmia
seems to be rare when there is preserved LV function and in
the absence of other predisposing factors such as electrolyte
disturbances [45, 46, 72]. A systematic review of seven trials
determined that the incidence of ventricular arrhythmias in
flecainide-treated patients was <3 % [123].
New or exacerbated ventricular arrhythmias occurred in
7 % of patients with PVBs, non-sustained or sustained VT.
Among patients treated for sustained VT (who frequently had
previous history of LV dysfunction, HF or MI), the incidence
of proarrhythmic events was 13 % when the treatment was
initiated at the dose of 200 mg/day and after titration did not
exceed 300 mg/day in most patients but increased to 26 %
when the starting dose was higher (400 mg/day). Because of
the high frequency of proarrhythmic events, flecainide is con-
traindicated in patients with sustained VT and underlying
heart disease, and drug therapy in suitable patients should be
started in the hospital.
The risk of proarrhythmia and other serious adverse effects
can be minimised (Table 3) by keeping strict adherence to
prescribing guidelines, with a better understanding of the
pharmacology of the drugs prescribed, limiting the number
of drugs prescribed, starting the treatment at low doses that
will be increased on the basis of the patient’s response and
comorbidities and performing regular monitoring of the ECG
and, if possible, of the drug plasma levels. As previously men-
tioned, even the self-administration of a single oral dose of
flecainide shortly after the onset of symptomatic AF (‘pill-in-
the-pocket’) can be administered to terminate persistent AF
outside the hospital only after treatment has been previously
proven safe in the hospital [40]. Importantly, current methods
of determining BE and therapeutic equivalence do not account
for PK variation and do not offer information regarding the
intra-patient variability, the differences in PKs that happen
within the same patient from dose to dose during the course
of drug therapy [124].
Drug interactions
The effects of drugs and other conditions on flecainide plasma
concentrations are summarised in Supplementary Table 2.
Generic substitution of brand-name AADs with a narrow
TI
When a patient is treated for a benign, non-life-threatening
disease with a drug that has a wide therapeutic window, ge-
neric substitution (i.e. switching between a branded drug and
its therapeutically equivalent generic version) is not a clinical
problem for many brand-name drugs. There might be, how-
ever, serious concerns about generic substitution for NTIDs in
which a relatively small change in drug plasma levels can
result in marked changes in PD response. For AADs such as
flecainide which show a steep dose–response relationship,
small changes in drug plasma levels can lead to successful
treatment, recurrence of the arrhythmia, a proarrhythmic event
or even death [2, 3]. Thus, it seems reasonable to avoid for-
mulation substitution from the brand-name drug to a generic
drug, from a generic drug to another generic drug or from a
generic drug to a brand-name drug, when the possible recur-
rence of the arrhythmia due to a lower drug plasma
Table 3 Recommendations to minimise the proarrhythmic effects of
flecainide
Recommendations
Keep strict adherence to prescribing guidelines
Avoid the use of flecainide in patients with structural heart disease
A better understanding of the pharmacology of the drugs prescribed
It will allow to identify possible drug interactions
Limit the number of drugs prescribed
Avoid the concomitant use of other antiarrhythmic drugs
Start the treatment at low doses that will be increased on the bases of
patient’s response and comorbidities
Increase dose after reaching steady-state levels (within 3–6 days)
Therapeutic drug monitoring (ECG, drug plasma levels) is recommended
when making drug adjustments
Particularly in the elderly and in patients with hepatic and/or renal
dysfunction
Monitor drug plasma levels to avoid toxic levels (>1000 ng/mL)
Check the efficiency and in particular the safety of the drug after the
transition from an in-hospital to the ambulatory setting
Pill-in-the-pocket approach: only when flecainide has been previously
proved safe in hospital and has a specific approval
ECG electrocardiogram
Eur J Clin Pharmacol (2015) 71:549–567 561
concentration or when an increase in drug plasma levels due to
a PK interaction can lead to a serious event for the patient. It
seems reasonable to avoid substitution if recurrence of the
arrhythmia being treated could be fatal when the tissue level
of the drug falls or if an increase in serum plasma levels of the
drug can also be associated with a life-threatening outcome,
such as a ventricular proarrhythmia, especially if warning
signs might not appear first.
For ethical reasons, the conventional BE studies between
generics and brand-name drugs are usually single-dose, two-
treatment crossover studies performed in a small number of
young healthy volunteers to minimise interindividual PK var-
iability. In this homogeneous population, PK endpoints can be
fairly consistent. However, the BE parameters change with
age or in the presence of a disease and flecainide is usually
prescribed in older patients (average age of patients with AF is
over 65 years) who present smaller body size (particularly
women), lower rates of hepatic metabolism and impaired renal
excretion and several other comorbidities that sensitise them
to the proarrhythmic effects of flecainide and most of them
(more than 80 %) take at least one drug every day increasing
the appearance of drug interactions [125]. Indeed flecainide
can interact with other antiarrhythmics and other drugs widely
prescribed in patients with frequent cardiac arrhythmias, such
as propranolol, diltiazem, verapamil or digoxin [45, 46] or
with non-cardiovascular drugs (Supplementary Table 2).
The question is whether the BE studies performed in small
numbers of fasting, healthy, normal volunteers, often homo-
geneous in characteristics such as age and gender, can be
extrapolated into therapeutic equivalence patients with a vari-
ety of disease conditions. Furthermore, although a difference
of 20 % between brand name and generic products is used to
define BE, it should be mentioned that BE relates to the mean
of the data for the study population, so values for individual
subjects may lie outside the BE intervals, even though the
mean ratios (and CIs) are within the limits [2, 3]. Because of
the steep dose–response curve of flecainide and the interindi-
vidual differences in drug metabolism and half-life, the 20 %
difference between products commonly used to define BE can
lead to small variations in drug exposure, leading to reduced
antiarrhythmic efficacy or adverse effects on patient out-
comes. Thus, it is not a surprise that some claim that under
these circumstances it would be desirable for BE tests to be
carried out on patients.
Some sparse evidence indicated that formulation substitu-
t ion involving AADs (quinidine , procainamide,
disopyramide, amiodarone) can be associated with clinical
equivalence, inequivalence [2, 3] and sometimes with adverse
clinical consequences [2, 3, 126–132]. Indeed a trend toward
differences in Cmax, tmax and AUC were reported for two pro-
prietary brands of sustained-release procainamide [127], and
adverse clinical consequences, including arrhythmia recur-
rence (associated with lower plasma concentrations) or
proarrhythmia (associated with higher plasma concentrations)
have been reported in association with generic substitution of
procainamide [128, 129], quinidine [133], amiodarone [2, 3]
and sotalol [3]. In most cases, arrhythmia control was re-
established when the patients were switched back to the
trade-name drug [2, 3]. These results can be attributed partly
to differences in drug absorption as BE studies were per-
formed in healthy volunteers while these older studies en-
rolled some post-myocardial patients in whom gastrointestinal
absorption is altered [134].
A survey of 130 expert electrophysiologists analysed their
experience with formulation substitution using AADs [124].
They provided 54 cases of recurrent tachyarrhythmia: 21 with
a class IA AADs, one with metoprolol and 32 with amioda-
rone following generic substitution. Among these recurrences,
there were three deaths due to VF, and more may have been
seen in the absence of implantable cardioverter defibrillator
backup, thus raising serious concerns about both AADs. In
one of the patients, there was a marked decrease in serum
amiodarone concentrations following a Pacerone substitution
for Cordarone (from 1.4 to 0.2 ng/mL). Another patient pre-
sented a recurrence of AF with a rapid ventricular response to
a quinidine formulation substitution, which simultaneously
resulted in a decline in the digoxin blood concentration. In
this case, formulation substitution resulted in a change in se-
rum and tissue levels of one drug which, in turn, led to chang-
es in the concentrations of a second agent if the PK of this
second agent is directly influenced by the amount of the first
agent [2, 3].
No study is available regarding the comparison of the TI of
flecainide under its two formulations: immediate release (IR)
and controlled release (CR). The effect of single- and
repeated-dose PKs and electrocardiographic effects (QRS du-
ration) of both formulations was performed in 24 healthy sub-
jects to examine the influence of CYP2D6 activity [87]. The
CR formulation produced a lower Cmax and delayed time to
reach Cmax; however, trough flecainide plasma concentration
at steady state was bioequivalent for both formulations, and
maximum andminimumQRS increases were not significantly
different for either the IR or the CR form of flecainide after
administration of both single and repeated doses. Mean QRS
duration during a dosing interval at steady state correlated
with mean plasma concentration for both forms, and CYP2D6
polymorphism did not appear to influence flecainide disposi-
tion kinetics or electrocardiographic effects at steady state.
Another comparative study in 48 patients with paroxysmal
AF between flecainide IR (100 mg BID) and CR (200 mg
OD) using QRS duration as the primary endpoint demonstrat-
ed ECG PD equivalence between both formulations. Howev-
er, there was a marked difference in circadian QRS variation
pattern, with peaks and troughs appearing with the IR formu-
lation but not under the CR formulation [135]. This result is
consistent with a greater occurrence of frequency-dependent
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QRS variations over the 24-h period with the IR compared
with the CR formulation.
Nevertheless, this evidence can be considered as anecdotal
case reports, although it can also be taken as hypothesis-
generating evidence for future comparisons between brand
name and generic drugs or even among different generics.
However, such comparative trials will not be performed in
the near future due to inadequate post-marketing funds avail-
able from the budgets of the innovator drugs and from the
generic manufacturers, lack of administrative support on both
sides of the Atlantic and perhaps concerns about marketing
risks, depending upon the outcome [2, 3].
Thus, the clinician should be aware for possible changes in
the PD effects when a brand name is substituted by a generic
or when switching between different generic products, partic-
ularly with drugs for which safe and effective use requires
careful titration and patient monitoring such as AADs. Thus,
generic substitution may not be advisable or even allowable
for NTIDs [55]. In fact, the American Medical Association
strongly recommends that therapeutic interchange in patients
with chronic diseases who are stabilised on a drug-therapy
regimen be discouraged and indicated that, especially for
drugs with a narrow therapeutic range, therapeutic drug con-
centration or PD monitoring is necessary to assure the desired
clinical response [136]. If formulation substitution is under-
taken, it is strongly recommended to employ rigorous moni-
toring of drug levels and/or ECG or other PDmarkers. Finally,
any prescriber of NTIDs must be clear on the differences
between brand name and generic drugs, as well as any report-
ed differences between generics [11].
Conclusions
Flecainide is an NTID not only for clinicians but also for
several regulatory agencies as well as for the American Col-
lege of Cardiology Foundation Clinical Quality Committee
[42]. Preclinical and clinical studies found that flecainide pre-
sents a steep dose–response curve that is even accentuated in
the presence of structural heart disease (particularly in the
ischaemic myocardium), evidence of potentially serious clin-
ical consequences when high flecainide plasma concentra-
tions are reached (although serious adverse effects have been
reported even at ‘therapeutic’ concentrations) and the need for
careful monitoring of the ECG and plasma drug levels under
several circumstances such as in patients with renal or hepatic
insufficiency. Cardiac adverse effects observed in patients
with cardiac arrhythmias include potentially severe and some-
times life-threatening proarrhythmic events, particularly in pa-
tients with structural heart disease (i.e. ischaemic heart disease
or HF). All of these characteristics confirm that flecainide can
be considered as an NTID.
However, flecainide is a drug of choice for themanagement
of patients with paroxysmal and persistent AF in carefully
selected groups of patients according to the ESC guidelines
because it is effective and has a good safety profile and a low
risk of ventricular proarrhythmia. To ensure that the benefits
of treatment outweigh the risks, a clear understanding of the
potential to produce proarrhythmic effects, careful selection of
patients and regular monitoring of the patient is essential for
the safe and rational administration of flecainide.
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